The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
PALJUNA MONTHLY (Juno Pharmaceuticals Pty Ltd)
Product name
PALJUNA MONTHLY
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
189 (255 working days)
Active ingredients
paliperidone palmitate
Registration type
New generic medicine
Indication
PALJUNA MONTHLY is indicated for the acute and maintenance treatment of schizophrenia in adults.